Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Foyou Pharma CoSHSE:601089 -0.47%55 EV-to-FCF is 44.10 as of Jul. 22, 2026, which is 126% above its 10-year median of 19.50. GuruFocus rates SHSE:601089 with a GF Score™ of 55/100 and a GF Value™ of ¥16.99 (Fairly Valued). The stock has 1 warning sign investors should review. Among 566 Drug Manufacturers companies, Beijing Foyou Pharma Co ranks worse than 69.79% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Beijing Foyou Pharma Co's Enterprise Value is ¥6,209 Mil.
Beijing Foyou Pharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥141 Mil. Therefore, Beijing Foyou Pharma Co's EV-to-FCF for today is 44.10.
The historical rank and industry rank for Beijing Foyou Pharma Co's EV-to-FCF or its related term are showing as below:
SHSE:601089'
s EV-to-FCF Range Over the Past 10 Years
Min: -303.91 Med: 19.5 Max: 231.71
Current: 44.1
During the past 8 years, the highest EV-to-FCF of Beijing Foyou Pharma Co was 231.71. The lowest was -303.91. And the median was 19.50.
SHSE:601089's EV-to-FCF is ranked worse than 69.79% of 566
companies
in the Drug Manufacturers industry
Industry Median: 20.945
vs SHSE:601089: 44.10
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beijing Foyou Pharma Co (SHSE:601089) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beijing Foyou Pharma Co's PE Ratio (TTM) for today is calculated as:
Beijing Foyou Pharma Co's share price for today is ¥16.77.
Beijing Foyou Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Foyou Pharma Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Foyou Pharma Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Foyou Pharma Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Beijing Foyou Pharma Co's EV-to-FCF falls into.
Beijing Foyou Pharma Co's current Enterprise Value is ¥6,209 Mil.
Beijing Foyou Pharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥141 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Foyou Pharma Co (SHSE:601089) has a EV-to-FCF of 44.10 as of Jul. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beijing Foyou Pharma Co and its competitors. This is 126% above median its historical median of 19.50. According to the industry distribution chart, Beijing Foyou Pharma Co ranks #395 out of 566 companies in the Drug Manufacturers industry, placing it in the top 69.8%.
Is Beijing Foyou Pharma Co's EV-to-FCF too high?
Beijing Foyou Pharma Co's current EV-to-FCF of 44.10 is 126% above median its 10-year median of 19.50. The Drug Manufacturers industry median EV-to-FCF is 20.95. Beijing Foyou Pharma Co's value of 44.10 is 110.6% above this industry median. Based on the distribution chart, Beijing Foyou Pharma Co ranks #395 out of 566 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Beijing Foyou Pharma Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beijing Foyou Pharma Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beijing Foyou Pharma Co ranks #395 out of 566 companies for EV-to-FCF. This places Beijing Foyou Pharma Co in the lower half of its industry. The industry median EV-to-FCF is 20.95. Beijing Foyou Pharma Co's value of 44.10 is 110.6% above this benchmark. While the company's 10-year median is 19.50 vs. the industry median of 20.95, Beijing Foyou Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.95, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Foyou Pharma Co's current EV-to-FCF of 44.10 is 110.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beijing Foyou Pharma Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Foyou Pharma Co's current EV-to-FCF is 44.10, which is 126% above median its own 10-year median of 19.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Foyou Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Foyou Pharma Co (SHSE:601089) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.99, compared to a current price of ¥16.77 — trading 1.3% below its estimated fair value. The current EV-to-FCF is 44.10, which is 126% above median its 10-year median of 19.50 and 110.6% above the Drug Manufacturers industry median of 20.95. Beijing Foyou Pharma Co's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Beijing Foyou Pharma Co (SHSE:601089), the current EV-to-FCF is 44.10 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Foyou Pharma Co (SHSE:601089) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Foyou Pharma Co stock appears to be undervalued.
The current stock price of ¥16.77 is trading 1.3% below its estimated GF Value™ of ¥16.99.
GuruFocus considers Beijing Foyou Pharma Co to be Fairly Valued.
Key valuation signals for SHSE:601089:
EV-to-FCF: 44.10 (126% above median its 10-year median of 19.50)
GF Value™: ¥16.99 vs. price of ¥16.77 (1.3% below fair value)
Industry Position: 110.6% above the Drug Manufacturers median (#395 of 566)
No single metric tells the full story. See the SHSE:601089 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:601089 has been successfully added to your 
